The Molecular Biomarker Revolution in Metastatic NSCLC

During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty will discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC. In addition, they will address how to integrate next generation sequencing (NGS) into your biomarker testing workflows and optimize its use for patients. Finally, th...